LRRK2 gene
leucine rich repeat kinase 2

Normal Function

The *LRRK2* gene provides instructions for making a protein called dardarin. The *LRRK2* gene is active in the brain and other tissues throughout the body.

One segment of the dardarin protein is called a leucine-rich region because it contains a large amount of a protein building block (amino acid) known as leucine. Proteins with leucine-rich regions appear to play a role in activities that require interactions with other proteins, such as transmitting signals or helping to assemble the cell's structural framework (cytoskeleton). Other parts of the dardarin protein are also thought to be involved in protein-protein interactions.

Additional studies indicate that dardarin has an enzyme function known as kinase activity. Proteins with kinase activity assist in the transfer of a phosphate group (a cluster of oxygen and phosphorus atoms) from the energy molecule ATP to amino acids in certain proteins. This phosphate transfer is called phosphorylation, and it is an essential step in turning on and off many cell activities. Dardarin also has a second enzyme function referred to as a GTPase activity. This activity is associated with a region of the protein called the ROC domain. The ROC domain may help control the overall shape of the dardarin protein.

Health Conditions Related to Genetic Changes

**Parkinson disease**

Researchers have identified more than 100 *LRRK2* gene mutations in families with late-onset Parkinson disease (the most common form of the disorder, which appears after age 50). These mutations replace single amino acids in the dardarin protein, which affects the protein's structure and function. It is unclear how *LRRK2* gene mutations lead to the movement and balance problems characteristic of Parkinson disease.

A mutation that replaces the amino acid arginine with the amino acid glycine at protein position 1441 (written as Arg1441Gly or R1441G) is a relatively common cause of Parkinson disease in the Basque region between France and Spain. The protein name dardarin comes from the Basque word "dardara," which means tremor, a characteristic feature of Parkinson disease.

Studies of several different populations from around the world revealed a common *LRRK2* gene mutation in 3 to 7 percent of familial Parkinson disease cases. This mutation replaces the amino acid glycine with the amino acid serine at protein
position 2019 (written as Gly2019Ser or G2019S). The incidence of the Gly2019Ser mutation in familial cases is highest among Arabs from North Africa and people of Ashkenazi (eastern and central European) Jewish ancestry, and it is lowest in Asian and northern European populations. This particular mutation has also been reported in 1 to 3 percent of sporadic Parkinson disease cases, in which there is no family history of the disease.

Studies in Chinese and Japanese populations have identified an LRRK2 gene mutation that occurs more frequently in people with Parkinson disease than in people without the disease. This mutation replaces the amino acid glycine with the amino acid arginine at protein position 2385 (written as Gly2385Arg or G2385R). This mutation appears to increase the risk of Parkinson disease among people in these populations.

**Crohn disease**

**Chromosomal Location**

Cytogenetic Location: 12q12, which is the long (q) arm of chromosome 12 at position 12

Molecular Location: base pairs 40,224,890 to 40,369,285 on chromosome 12 (Homo sapiens Updated Annotation Release 109.20200522, GRCh38.p13) (NCBI)

Credit: Genome Decoration Page/NCBI

**Other Names for This Gene**

- DRDN
- leucine-rich repeat kinase 2
- LRRK2_HUMAN
- PARK8
- RIPK7
- ROCO2
Additional Information & Resources

Clinical Information from GeneReviews

- LRRK2 Parkinson Disease
  https://www.ncbi.nlm.nih.gov/books/NBK1208

- Parkinson Disease Overview
  https://www.ncbi.nlm.nih.gov/books/NBK1223

Scientific Articles on PubMed

- PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28%28LRRK2%5BTIAB%5D%29+OR+%28leucine-rich+repeat+kinase+2%5BTIAB%5D%29+OR+%28PARK8%5BTIAB%5D%29+OR+%28dardarin%5BTIAB%5D%29%29+AND+%28%28Genes%5BMH%5D+OR+%28Genetic+Phenomena%5BMH%5D%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+720+days%22%5Bdp%5D

Catalog of Genes and Diseases from OMIM

- LEUCINE-RICH REPEAT KINASE 2
  http://omim.org/entry/609007

Research Resources

- Atlas of Genetics and Cytogenetics in Oncology and Haematology
  http://atlasgeneticsoncology.org/Genes/GC_LRRK2.html

- ClinVar
  https://www.ncbi.nlm.nih.gov/clinvar?term=LRRK2%5Bgene%5D

- HGNC Gene Symbol Report
  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18618

- Monarch Initiative
  https://monarchinitiative.org/gene/NCBIGene:120892

- NCBI Gene
  https://www.ncbi.nlm.nih.gov/gene/120892

- PDGene
  http://www.pdgene.org/view?gene=LRRK2

- UniProt
  https://www.uniprot.org/uniprot/Q5S007
Sources for This Summary

- Bonifati V. LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson's disease. Neurochem Res. 2007 Oct;32(10):1700-8. Epub 2007 Apr 18. Review. 
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17440812

- Cookson MR. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci. 2010 Dec;11(12):791-7. doi: 10.1038/nrn2935. Epub 2010 Nov 19. Review. 
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21088684 
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662256/

- Di Fonzo A, Rohé CF, Ferreira J, Chien HF, Vacca L, Stocchi F, Guedes L, Fabrizio E, Manfredi M, Vanacore N, Goldwurm S, Breedveld G, Sampaio C, Meco G, Barbosa E, Oostra BA, Bonifati V; Italian Parkinson Genetics Network. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet. 2005 Jan 29-Feb 4;365(9457):412-5. 
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15680456

- Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, Shaw K, Bhatia KP, Bonifati V, Quinn NP, Lynch J, Healy DG, Holton JL, Revesz T, Wood NW. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet. 2005 Jan 29-Feb 4;365(9457):415-6. 
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15680457

- Guo L, Wang W, Chen SG. Leucine-rich repeat kinase 2: relevance to Parkinson's disease. Int J Biochem Cell Biol. 2006;38(9):1469-75. Epub 2006 Mar 2. Review. 
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16600664

- Kumar A, Cookson MR. Role of LRRK2 kinase dysfunction in Parkinson disease. Expert Rev Mol Med. 2011 Jun 13;13:e20. doi: 10.1017/S146239941100192X. Review. 
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21676337 
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672634/

- Lesage S, Dürr A, Tazir M, Lohmann E, Leutenegger AL, Janin S, Pollak P, Brice A; French Parkinson's Disease Genetics Study Group. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med. 2006 Jan 26;354(4):422-3. 
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16436781

- Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 2006 May;29(5):286-93. Epub 2006 Apr 17. Review. 
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16616379

- Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, Hunt AL, Klein C, Henick B, Hailpern SM, Lipton RB, Soto-Valencia J, Risch N, Bressman SB. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med. 2006 Jan 26;354(4):424-5. 
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16436782
Ross OA, Soto-Ortolaza AI, Heckman MG, Aasly JO, Abahuni N, Annesi G, Bacon JA, Bardien S, Bozi M, Brice A, Brighina L, Van Broeckhoven C, Carr J, Chartier-Harlin MC, Dardiotis E, Dickson DW, Diehl NN, Elbaz A, Ferrarese C, Ferraris A, Fiske B, Gibson JM, Gibson R, Hadjigeorgiou GM, Hattori N, Ioannidis JP, Jasinska-Myga B, Jeon BS, Kim YJ, Klein C, Kruger R, Kyratzi E, Lesage S, Lin CH, Lynch T, Maraganore DM, Mellick GD, Mutez E, Nilsson C, Opala G, Park SS, Puschmann A, Quattrone A, Sharma M, Silburn PA, Sohn YH, Stefanis L, Tadic V, Theuns J, Tomiyama H, Uitti RJ, Valente EM, van de Loo S, Vassilatis DK, Vilarino-Güell C, White LR, Wirdefeldt K, Wszolek ZK, Wu RM, Farrer MJ; Genetic Epidemiology Of Parkinson's Disease (GEO-PD) Consortium. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol. 2011 Oct;10(10):898-908. doi: 10.1016/S1474-4422(11)70175-2. Epub 2011 Aug 30. Erratum in: Lancet Neurol. 2011 Oct;10(10):870. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21885347 Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208320/

Smith WW, Pei Z, Jiang H, Moore DJ, Liang Y, West AB, Dawson VL, Dawson TM, Ross CA. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18676-81. Epub 2005 Dec 13. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16352719 Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1317945/

Tan EK, Zhao Y, Skipper L, Tan MG, Di Fonzo A, Sun L, Fook-Chong S, Tang S, Chu E, Yuen Y, Tan L, Pavanni R, Wong MC, Kolatkar P, Lu CS, Bonifati V, Liu JJ. The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. Hum Genet. 2007 Feb;120(6):857-63. Epub 2006 Sep 30. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17019612

West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16842-7. Epub 2005 Nov 3. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16289341 Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1283829/

Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Müller-Mylsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004 Nov 18;44(4):601-7. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15541309

Reprinted from Genetics Home Reference: https://ghr.nlm.nih.gov/gene/LRRK2

Reviewed: May 2012
Published: June 23, 2020

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services